Literature DB >> 30008018

Plasma microRNAs as biomarkers for Lamin A/C-related dilated cardiomyopathy.

Rocío Toro1, Sara Blasco-Turrión2, Francisco José Morales-Ponce2, Pablo Gonzalez2, Pablo Martínez-Camblor3,4, Amador López-Granados5, Ramon Brugada6,7,8,9, Oscar Campuzano6,7,8, Alexandra Pérez-Serra6,8, Felix Rosa Longobardo10, Alipio Mangas10,11, Vicenta Llorente-Cortes8,12,13, David de Gonzalo-Calvo14,15,16.   

Abstract

Lamin A/C gene (LMNA)-related familial dilated cardiomyopathy (fDCM) is an aggressive heart disease that often leads to transplantation and sudden death. The aim of our study was to evaluate the circulating microRNA (miRNA) profiles of patients with LMNA pathogenic mutations. The study population (N = 75) included (i) patients with pathogenic LMNA mutations responsible for fDCM (LMNAMUT), (ii) age- and sex-matched LMNA wild-type controls (LMNAWT control), and (iii) LMNA wild-type idiopathic DCM (iDCM) patients (LMNAWT iDCM). Detailed clinical information was obtained from each participant. A panel of 179 plasma miRNAs was evaluated using RT-qPCR. An initial screening study was performed in LMNAMUT carriers and age-matched LMNAWT controls (N = 16). Forty-four miRNAs were specifically deregulated in LMNAMUT carriers. Ten miRNA candidates were selected for subsequent validation after coexpression analyses and filtered for expression levels and statistical significance. Among the candidates, let-7a-5p, miR-142-3p, miR-145-5p and miR-454-3p levels were significantly increased in LMNAMUT carriers compared to LMNAWT controls and iDCM patients (P < 0.050). These circulating miRNAs, and their combination, were also associated with the presence of pathogenic mutations in regression and ROC analyses. This signature also discriminates between LMNAWT healthy subjects and LMNAMUT carriers who are phenotypically negative for DCM and between LMNAWT iDCM and LMNA-related DCM patients. Correlation and functional enrichment analyses supported their association with the pathophysiology of the disease. We demonstrated for the first time that a specific miRNA signature could serve as a novel non-invasive tool to assist in the diagnosis of patients with fDCM caused by LMNA pathogenic mutations. KEY MESSAGES: Let-7a-5p, miR-142-3p, miR-145-5p and miR-454-3p are differentially expressed in LMNAMUT carriers. A composite score based on these miRNAs is a biomarker of mutations in the LMNA gene. This miRNA signature can be associated with the pathophysiology of familial DCM. The circulating miRNA profile can assist in the diagnosis of familial DCM.

Entities:  

Keywords:  Biomarkers; Circulating microRNAs; Dilated cardiomyopathy; Lamin A/C (LMNA)

Mesh:

Substances:

Year:  2018        PMID: 30008018     DOI: 10.1007/s00109-018-1666-1

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  39 in total

1.  Circulating microRNA as a biomarker for recovery in pediatric dilated cardiomyopathy.

Authors:  Shelley D Miyamoto; Anis Karimpour-Fard; Valencia Peterson; Scott R Auerbach; Kurt R Stenmark; Brian L Stauffer; Carmen C Sucharov
Journal:  J Heart Lung Transplant       Date:  2015-01-30       Impact factor: 10.247

Review 2.  Transcriptome of blood cells as a reservoir of cardiovascular biomarkers.

Authors:  Yvan Devaux
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2016-11-09       Impact factor: 4.739

Review 3.  Circulating Noncoding RNAs as Biomarkers of Cardiovascular Disease and Injury.

Authors:  Janika Viereck; Thomas Thum
Journal:  Circ Res       Date:  2017-01-20       Impact factor: 17.367

4.  2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).

Authors:  Silvia G Priori; Carina Blomström-Lundqvist; Andrea Mazzanti; Nico Blom; Martin Borggrefe; John Camm; Perry Mark Elliott; Donna Fitzsimons; Robert Hatala; Gerhard Hindricks; Paulus Kirchhof; Keld Kjeldsen; Karl-Heinz Kuck; Antonio Hernandez-Madrid; Nikolaos Nikolaou; Tone M Norekvål; Christian Spaulding; Dirk J Van Veldhuisen
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

5.  Long-term outcome and risk stratification in dilated cardiolaminopathies.

Authors:  Michele Pasotti; Catherine Klersy; Andrea Pilotto; Nicola Marziliano; Claudio Rapezzi; Alessandra Serio; Savina Mannarino; Fabiana Gambarin; Valentina Favalli; Maurizia Grasso; Manuela Agozzino; Carlo Campana; Antonello Gavazzi; Oreste Febo; Massimiliano Marini; Maurizio Landolina; Andrea Mortara; Giovanni Piccolo; Mario Viganò; Luigi Tavazzi; Eloisa Arbustini
Journal:  J Am Coll Cardiol       Date:  2008-10-07       Impact factor: 24.094

Review 6.  The Diagnosis and Evaluation of Dilated Cardiomyopathy.

Authors:  Alan G Japp; Ankur Gulati; Stuart A Cook; Martin R Cowie; Sanjay K Prasad
Journal:  J Am Coll Cardiol       Date:  2016-06-28       Impact factor: 24.094

7.  Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure.

Authors:  Jian-Fu Chen; Elizabeth P Murchison; Ruhang Tang; Thomas E Callis; Mariko Tatsuguchi; Zhongliang Deng; Mauricio Rojas; Scott M Hammond; Michael D Schneider; Craig H Selzman; Gerhard Meissner; Cam Patterson; Gregory J Hannon; Da-Zhi Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-06       Impact factor: 11.205

8.  Genomic structural variations lead to dysregulation of important coding and non-coding RNA species in dilated cardiomyopathy.

Authors:  Jan Haas; Stefan Mester; Alan Lai; Karen S Frese; Farbod Sedaghat-Hamedani; Elham Kayvanpour; Tobias Rausch; Rouven Nietsch; Jes-Niels Boeckel; Avisha Carstensen; Mirko Völkers; Carsten Dietrich; Dietmar Pils; Ali Amr; Daniel B Holzer; Diana Martins Bordalo; Daniel Oehler; Tanja Weis; Derliz Mereles; Sebastian Buss; Eva Riechert; Emil Wirsz; Maximilian Wuerstle; Jan O Korbel; Andreas Keller; Hugo A Katus; Andreas E Posch; Benjamin Meder
Journal:  EMBO Mol Med       Date:  2018-01       Impact factor: 12.137

9.  Circulating non-coding RNAs in biomarker-guided cardiovascular therapy: a novel tool for personalized medicine?

Authors:  David de Gonzalo-Calvo; Angela Vea; Christian Bär; Jan Fiedler; Liam S Couch; Carlos Brotons; Vicenta Llorente-Cortes; Thomas Thum
Journal:  Eur Heart J       Date:  2019-05-21       Impact factor: 29.983

10.  A signature of circulating microRNAs differentiates takotsubo cardiomyopathy from acute myocardial infarction.

Authors:  Milosz Jaguszewski; Julia Osipova; Jelena-Rima Ghadri; Lars Christian Napp; Christian Widera; Jennifer Franke; Marcin Fijalkowski; Radoslaw Nowak; Marta Fijalkowska; Ingo Volkmann; Hugo A Katus; Kai C Wollert; Johann Bauersachs; Paul Erne; Thomas F Lüscher; Thomas Thum; Christian Templin
Journal:  Eur Heart J       Date:  2013-09-17       Impact factor: 29.983

View more
  9 in total

1.  Immune checkpoint inhibitor induces cardiac injury through polarizing macrophages via modulating microRNA-34a/Kruppel-like factor 4 signaling.

Authors:  Wenzheng Xia; Changlin Zou; Hanbin Chen; Congying Xie; Meng Hou
Journal:  Cell Death Dis       Date:  2020-07-24       Impact factor: 8.469

2.  Substantially Altered Expression Profile of Diabetes/Cardiovascular/Cerebrovascular Disease Associated microRNAs in Children Descending from Pregnancy Complicated by Gestational Diabetes Mellitus-One of Several Possible Reasons for an Increased Cardiovascular Risk.

Authors:  Ilona Hromadnikova; Katerina Kotlabova; Lenka Dvorakova; Ladislav Krofta; Jan Sirc
Journal:  Cells       Date:  2020-06-26       Impact factor: 6.600

3.  Head and neck squamous cancer progression is marked by CLIC4 attenuation in tumor epithelium and reciprocal stromal upregulation of miR-142-3p, a novel post-transcriptional regulator of CLIC4.

Authors:  Brandi L Carofino; Kayla M Dinshaw; Pui Yan Ho; Christophe Cataisson; Aleksandra M Michalowski; Andrew Ryscavage; Addie Alkhas; Nathan W Wong; Vishal Koparde; Stuart H Yuspa
Journal:  Oncotarget       Date:  2019-12-31

4.  Circulating circRNA as biomarkers for dilated cardiomyopathy etiology.

Authors:  Marina C Costa; Maria Calderon-Dominguez; Alipio Mangas; Oscar Campuzano; Georgia Sarquella-Brugada; Mónica Ramos; Maribel Quezada-Feijoo; José Manuel García Pinilla; Ainhoa Robles-Mezcua; Galan Del Aguila Pacheco-Cruz; Thalia Belmonte; Francisco J Enguita; Rocío Toro
Journal:  J Mol Med (Berl)       Date:  2021-09-08       Impact factor: 4.599

5.  lncRNA ADAMTS9-AS1/circFN1 Competitively Binds to miR-206 to Elevate the Expression of ACTB, Thus Inducing Hypertrophic Cardiomyopathy.

Authors:  Wei Feng; Shuo Han
Journal:  Oxid Med Cell Longev       Date:  2022-03-31       Impact factor: 6.543

6.  MicroRNA expression profiling involved in doxorubicin-induced cardiotoxicity using high-throughput deep-sequencing analysis.

Authors:  Ying Chen; Yingjie Xu; Zhoufeng Deng; Yin Wang; Ying Zheng; Weihua Jiang; Li Jiang
Journal:  Oncol Lett       Date:  2021-05-26       Impact factor: 2.967

7.  Diabetes Mellitus and Cardiovascular Risk Assessment in Mothers with a History of Gestational Diabetes Mellitus Based on Postpartal Expression Profile of MicroRNAs Associated with Diabetes Mellitus and Cardiovascular and Cerebrovascular Diseases.

Authors:  Ilona Hromadnikova; Katerina Kotlabova; Lenka Dvorakova; Ladislav Krofta
Journal:  Int J Mol Sci       Date:  2020-03-31       Impact factor: 5.923

8.  Forced expression of miR-143 and -145 in cardiomyocytes induces cardiomyopathy with a reductive redox shift.

Authors:  Jun Ueda; Takehiro Ogata; Kota Ogawa; Akiko Noda; Rumiko Matsuyama; Yuji Nishizawa; Shanlou Qiao; Satoru Iwata; Morihiro Ito; Yoshitaka Fujihara; Masatoshi Ichihara; Koichi Adachi; Yuji Takaoka; Takashi Iwamoto
Journal:  Cell Mol Biol Lett       Date:  2020-08-24       Impact factor: 5.787

9.  Integrated Analysis of Hub Genes and miRNAs in Dilated Cardiomyopathy.

Authors:  Kai Huang; Shuyan Wen; Jiechun Huang; Fangrui Wang; Liewen Pang; Yiqing Wang; Xiaotian Sun
Journal:  Biomed Res Int       Date:  2020-09-15       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.